Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: A randomised controlled trial

Archives of Gynecology and Obstetrics

Volumn 277, Issue 6, 2008, Pages 489-493

  Kumru, Selahattin ^a   Yildiz, Fahrettin M ^a   Godekmerdan, Ahmet ^a   Kutlu, Selim ^a   Yilmaz, Bayram ^a   Gurates, Bilgin ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

HRT; IL 4; Menopause; Raloxifene; TGF 1

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; INTERLEUKIN 4; PLACEBO; RALOXIFENE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE; AMENORRHEA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; WILCOXON SIGNED RANKS TEST;

BONE DENSITY CONSERVATION AGENTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTERLEUKIN-4; MIDDLE AGED; NANDROLONE; POSTMENOPAUSE; RALOXIFENE; SINGLE-BLIND METHOD; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 42649137935     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-007-0521-3     Document Type: Article

References (35)

1. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE et al (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 20:2663-2672
2. Practice Committee of the Americal Society for Reproductive Medicine (2004) Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 1:231-1241
3. Greendale GA, Lee NP, Arriola ER (1999) The menopause Lancet 353:571-580
4. Solerte SB, Fioravanti M Racchi M, Trabucchi M, Zanetti O, Govoni S (1999) Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas 31:95-101
5. Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H et al (2006) Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Maturitas 2:191-200
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al, WHI Investigators and McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253
7. Million Women Study Collaborators, Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
8. Stevenson JC (2006) HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Hum Reprod 7:1668-1671
9. Cohen JH, Danel L, Cordier G, Saez S, Revillard JP (1983) Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol 6:2767-2771
10. Danel L, Souweine G, Monier JC, Saez S (1983) Specific estrogen binding sites in human lymphoid cells and thymic cells. J Steroid Biochem 5:559-563
11. Kanda N, Tamaki K (1999) Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 103:282-288
12. Verthelyi D, Ahmed SA (1994) 17 beta-estradiol, but not 5 alpha-dihydrotestosterone, augments antibodies to double-stranded deoxyribonucleic acid in nonauto-immune C57BL/6J mice. Endocrinology 135:2615-2622
13. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB (2001) Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol 36:311-326
14. Kumru S, Godekmerdan A, Yilmaz B (2004) Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. J Reprod Immunol 1:31-38
15. Stopinska-Gluszak U, Waligora J, Grzela T, Gluszak M, Jozwiak J, Radomski D, et al (2006) Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women. J Reprod Immunol 1:65-75
16. Graser T, Romer T, Wiedey KD, Janaud A (2001) Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 4:332-342
17. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al (2005) Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 9:1514-1524
18. Rogers A, Clowes JA, Pereda CA, Eastell R (2007) Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies. Bone 1:105-110
19. Murase Y, Kobayashi J, Asano A, Yamaaki N, Yonezawa K, Muramoto H, et al (2006) Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes. Horm Metab Res 2:130-133
20. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S (2005) Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet 2:128-133
21. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173
22. Romagnani S (1991) Human TH1 and TH2 subsets: doubt no more.Immunol. Today 8:256-257
23. Klouche M (2006) Estrogens in human vascular diseases. Ann N Y Acad Sci 1089:431-43
24. Kohen F, Abel L, Sharp A, Amir-Zaltsman Y, Sömjen D, Lurşa S, et al (1998) Dev Immunol 4:277-85
25. Suenaga R, Evans MJ, Mitamura K, Rider V, Abdou NI (1998) Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J Rheumatol 7:1305-1312
26. Reginster JY, Devogelaer JP (2006) Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin Orthop Relat Res 443:48-54
27. Karpuzoglu E, Ahmed SA (2006) Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide 3:177-86
28. Fox HS, Bond BL, Parslow TG (1991) Estrogen regulates the IFN-gamma promoter. J Immunol 12:4362-4367
29. Piccinni MP (2006) T cells in normal pregnancy and recurrent pregnancy loss. Reprod Biomed Online 6:840-844
30. Kudravi SA, Reed MJ (2000) Aging, cancer, and wound healing. In Vivo 1:83-92
31. Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 1:32-46
32. Roberts AB, Sporn MB (1990) The transforming growth factors. In: Sporn MB, Roberts AB (eds) Peptide growth factors and their receptors. Springer, Berlin, pp 419-472
33. Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE (1991) Coordinated regulation of apoptosis and cell proliferation by transforming growth factor 81 in cultured uterine epithelial cells. Proc Nat1 Acad Sci USA 88:3412-3415
34. Mendez-Davila C, Garcia-Moreno C, Turbi C, de la Piedra C (2004) Effects of 17 beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J Endocrinol Invest 10:904-912
35. Lee KM, Kim YK (2006) The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 8:1298-1304